$XBI $126.19 -1.9%
Covid Updates
$VALN +24.3% Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001. source
Pipeline Updates
$ABUS -0.6% Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting® source
$ATHA -4.1% Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference source
$URGN -0.6% UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event source
$DRRX -4.7% DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis. source
$ALEC -2.8% Alector Presents New Data from Multiple Pipeline Programs at 2021 CTAD Conference. source
$PHAS +1.8% PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting. source
$MBIO -2.8% Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency. source
$HEPA -0.7% Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021. source
$AUTL -3.5% Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells. source
$GLSI -1.5% Greenwich LifeSciences Provides Clinical Update on Upcoming Phase III Clinical Trial, FLAMINGO-01. source
$EVFM -2.1% Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive. source
$KALV -0.1% KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema. source
$ERYP -4.2% ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal. source
Financial Updates
$IMAB +4.5% I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa. source
$MCRB +20.4% Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection. source
Posted by FS/JM
Comments